Resected Adenocarcinoma of the Pancreas - 616 Patients: Results, Outcomes, and Prognostic Indicators

Journal of Gastrointestinal Surgery

Volumn 4, Issue 6, 2000, Pages 567-579

  Sohn, Taylor A ^a   Yeo, Charles J ^a   Cameron, John L ^a   Koniaris, Leonidas ^a   Kaushal, Sunjay ^a   Abrams, Ross A ^a   Sauter, Patricia K ^a   Coleman, Joann ^a   Hruban, Ralph H ^a   Lillemoe, Keith D ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Adenocarcinoma; Pancreatic cancer; Prognostic factors; Survival

Indexed keywords

ADENOCARCINOMA; ADJUVANT THERAPY; AGED; ANALYSIS OF VARIANCE; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MARYLAND; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034329115     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(00)80105-5     Document Type: Article

References (48)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996;223:506-512.
3. Crile G Jr. The advantages of bypass over radical pancreaticoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 1970;130:1049-1053,
4. Shapiro TM. Adenocarcinoma of the pancreas. A statistical analysis of bypass vs. Whipple resection in good risk patients. Ann Surg 1975;182:715-721.
5. Crist DL, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality and survival after the Whipple procedure. Ann Surg 1987;206:358-365.
6. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 217:43-49.
7. Trede M, Schwall G, Saeger H-D. Survival after pancreaticoduodenectomy: 118 consecutive resections without a mortality. Ann Surg 1990;211:447-458.
8. Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217:430-438.
9. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancrearicoduodenectomies in the 1990s: Pathology, complications, outcomes. Ann Surg 1997;226:248-260.
10. Gordon TA, Burleyson GP, Tielsch JM, et al. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995;221:43-49.
11. Sosa JA, Bowman HM, Bass EB, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:429-438.
12. Lieberman MD, Kilburn H, Lindsey, et al. Relation of peri-operative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222:638-645.
13. Coquard R, Ayzae L, Romestaing P, et al. Adenocarcinoma of the body and tail of the pancreas: Is there room for adjuvant radiotherapy? Tumori 1997;83;740-742.
14. Dalton RR, Sarr MG, van Heerden JA, et al. Carcinoma of the body and tail of the pancreas: Is curative resection justified? Surgery 1992;111:489-494.
15. Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas: Implications for radiation therapy. Ann Surg 1993;217:144-148.
16. Allison DC, Bose KK, Hruban RH, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreaticoduodenectomy. Ann Surg 1991;214:648-656.
17. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995;221:721-733.
18. Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic carcinoma. Cancer Res 1994;54:2761-2764.
19. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-3033.
20. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-636.
21. Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma: Analysis of 5-year survivors, Ann Surg 1998;227: 821-831.
22. Delcore R, Rodriquez FJ, Forster J, et al. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg 1996;172:463-469.
23. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection of pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223:273-279.
24. 1 carcinoma of the pancreas. Surg Gynecol Obstet 1992;175: 259-265.
25. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. A multicenter, prospective, randomized study. Ann Surg 1998;228:508-517.
26. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Comparison of morbidity, mortality, and short-term outcome. Ann Surg 1999; 229:613-623.
27. Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995; 222:580-592.
28. Yeo CJ, Barry MK, Sauter PK, et al. Erythromycin accelerates gastric emptying following pancreaticoduodenectomy: A prospective, randomized, placebo-controlled trial. Ann Surg 1993;218:229-238.
29. Kalser MH, Ellenberg SS. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
30. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006-2010.
31. Carducci MA, Abrams RA, Yeo CJ, et al. Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. Int J Radiat Oncol Biol Phys 1996;35:143-150.
32. Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA 19-9 levels. Int J Radiat Oncol Biol Phys 1999;44:1039-1046.
33. Chakravarthy A, Abrams RA, Yeo CJ, et al. Intensified adjuvant combined modality therapy for resected pancreatic and periampullary adenocarcinoma: Acceptable toxicity with improved early results. Int J Radiat Oncol Biol Phys (in press).
34. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
35. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
36. Herbert PC, Well G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-417.
37. Neoptolemos JP, Baker P, Beger H, et al. Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ES-PAC-1). Int J Pancreatol 1997;21:97-104.
38. Klinkenbijl JH, Jeekel J, Shamoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal cooperative group. Ann Surg 1999; 230:776-782.
39. Sharp KW, Ross CB, Halter SA, et al. Pancreaticoduodenectomy with pyloric preservation for carcinoma of the pancreas. A cautionary note. Surgery 1989;105:645-653.
40. Roder JD, Stein HJ, Huttl W, et al. Pylorus-preserving versus standard pancreaticoduodenectomy: An analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 1992;79:152-155.
41. Grace PA, Pitt HA, Longmire WP. Pylorus-preserving pancreaticoduodenectomy: An overview. Br J Surg 1990;77:968-974.
42. Wenger FA, Jacobi CA, Haubold K, et al. Gastrointestinal quality of life after duodenopancreatectomy in pancreatic carcinoma. Preliminary results of a prospective randomized study: Pancreatoduodenectomy or pylorus-preserving pancreatoduodenectomy. Chirurg 1999;70:1454-1459.
43. Seiler CA, Wagner M, Sadowski C, et al. Randomized prospective trial of pylorus-preserving vs. classic duodenopancreatectomy (Whipple procedure): Initial clinical results. J GASTROINTEST SURG 2000;4:443-452.
44. Takada T, Yasuda H, Shikita JI, et al. Postprandial plasma gastrin and secretin concentrations after pancreatoduodenectomy. Ann Surg 1989;210:47-51.
45. Williamson RCN, Bliouras N, Cooper MJ, et al. Gastric emptying and enterogastric reflux after conservative and conventional pancreatoduodenectomy. Surgery 1993;114:82-86.
46. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal mutinous cell hyperplasia. Cancer Res 1994;54:3568-3573.
47. Berthelemy P, Bouisson M, Escourrrou J, et al. Identification of K-ras mutations in pancreatic juice early in the diagnosis of pancreatic cancer. Ann Intern Med 1998;123:188-191.
48. Wilentz RE, Chung CH, Sturm PDJ, et al. K-ras mutations in duodenal fluid of patients with pancreas carcinoma. Cancer 1998;82:96-103.